以中国健康受试者为试验对象，采用自身交叉对照的试验设计，测定江苏德源药业股份有限公司研制生产的利格列汀二甲双胍缓释片[规格：每片含利格列汀5 mg和盐酸二甲双胍1000 mg]给药后利格列汀和二甲双胍在健康受试者体内的血药浓度经时过程，估算相应的药代动力学参数，并以Boehringer Ingelheim Pharmaceuticals, Inc.持证的利格列汀二甲双胍缓释片（商品名：Jentadueto®XR）为参比制剂，考察受试制剂的相对生物利用度，评价制剂间的生物等效性，并观察受试制剂和参比制剂在中国健康受试者中的安全性。

[Translation]

Methods: Chinese healthy subjects were used as test subjects. A self-crossover design was used to determine the time course of plasma concentrations of linagliptin and metformin in healthy subjects after administration of linagliptin and metformin extended-release tablets [specification: each tablet contains 5 mg linagliptin and 1000 mg metformin hydrochloride] developed and produced by Jiangsu Deyuan Pharmaceutical Co., Ltd., and the corresponding pharmacokinetic parameters were estimated. Linagliptin and metformin extended-release tablets (trade name: Jentadueto® XR) certified by Boehringer Ingelheim Pharmaceuticals, Inc. was used as the reference preparation to investigate the relative bioavailability of the test preparation, evaluate the bioequivalence between the preparations, and observe the safety of the test preparation and the reference preparation in Chinese healthy subjects.

Start Date26 Apr 2025

Sponsor / Collaborator

Jiangsu Deyuan Pharmaceutical Co., Ltd.

CTR20251133

/ CompletedNot Applicable

利格列汀二甲双胍缓释片在健康人群中的生物等效性试验

[Translation] Bioequivalence study of linagliptin and metformin extended-release tablets in healthy subjects

在健康受试者体内，分别在空腹和餐后条件下，以Boehringer Ingelheim pharmaceuticals,Inc.持有的利格列汀二甲双胍缓释片为参比制剂，研究北京福元医药股份有限公司研制的利格列汀二甲双胍缓释片的吸收速度与吸收程度，评价受试制剂与参比制剂是否具有生物等效性。观察健康受试者口服受试制剂和参比制剂的安全性。

[Translation]

In healthy subjects, the absorption rate and extent of Linagliptin Metformin Sustained-Release Tablets developed by Beijing Fuyuan Pharmaceutical Co., Ltd. were studied under fasting and postprandial conditions, using Linagliptin Metformin Sustained-Release Tablets owned by Boehringer Ingelheim Pharmaceuticals, Inc. as the reference preparation, and the bioequivalence of the test preparation and the reference preparation was evaluated. The safety of the test preparation and the reference preparation when taken orally was observed in healthy subjects.

Start Date04 Apr 2025

Sponsor / Collaborator

Beijing Winsunny Pharmaceutical Co., Ltd.

CTIS2024-516081-11-00

/ Not yet recruitingPhase 1

- N-LINMET-24-290

Start Date16 Dec 2024

Sponsor / Collaborator-

100 Clinical Results associated with Linagliptin/Metformin Hydrochloride

100 Translational Medicine associated with Linagliptin/Metformin Hydrochloride

100 Patents (Medical) associated with Linagliptin/Metformin Hydrochloride

Literatures (Medical) associated with Linagliptin/Metformin Hydrochloride

01 Jan 2019·Journal of pharmaceutical and biomedical analysisQ3 · MEDICINE

A validated LC-MS/MS method for simultaneous determination of linagliptin and metformin in spiked human plasma coupled with solid phase extraction: Application to a pharmacokinetic study in healthy volunteers

Q3 · MEDICINE

Article

Author: Abbas Moussa, Bahia ; Mahrouse, Marianne Alphonse ; Fawzy, Michael Gamal

Combination therapy has a pivotal role in type II diabetes mellitus management in patients unable to maintain normal glycemic level using metformin alone. Addition of linagliptin, dipeptidyl peptidase-IV inhibitor, to metformin improves glycemic control. This study is concerned with the development of an HPLC-MS/MS method for simultaneous quantification of linagliptin and metformin in spiked human plasma. The method was applied to evaluate the potential pharmacokinetic interactions between the cited drugs in healthy volunteers. Solid phase extraction was applied using Strata™ X cartridge. Separation was carried out on Symmetry^® C₁₈ column using methanol: 10 mM ammonium formate buffer (containing 0.2% formic acid) in a ratio of (95: 5, v/v) as mobile phase at flow rate 0.25 mL min^-1. Quantification was performed with multiple reaction monitoring in positive ionization mode. The monitored transitions were set at m/z 473.24 → 419.94, 130.14 → 60.18 and 340.27 → 116.07 for linagliptin, metformin and alogliptin (internal standard), respectively. The method was validated according to FDA guidelines. The method showed excellent linearity over concentration ranges 0.25-10 and 25-2000 ng mL^-1 for linagliptin and metformin, respectively. The validated HPLC-MS/MS method was successfully applied to pharmacokinetic study of linagliptin and metformin in healthy volunteers after oral administration of Jentadueto^® tablets.

01 Oct 2014·DrugsQ1 · MEDICINE

Linagliptin: An Update of Its Use in Patients with Type 2 Diabetes Mellitus

Q1 · MEDICINE

Review

Author: McKeage, Kate

Linagliptin (Trajenta(®), Tradjenta(®)) is a dipeptidyl peptidase (DPP)-4 inhibitor approved for the treatment of adults with type 2 diabetes mellitus in several countries. A fixed-dose combination of linagliptin/metformin (Jentadueto(®)) is also available. This article reviews the pharmacology, therapeutic efficacy and tolerability of linagliptin in the management of type 2 diabetes, with the aim of updating its place in therapy based on recently published data. In randomized, controlled trials, oral linagliptin 5 mg once daily (or 2.5 mg twice daily when combined with metformin) improved glycaemic control when used alone or in combination with other antidiabetic agents, including metformin, a sulfonylurea, thiazolidinedione or insulin. Improvements in glycaemic control were also shown in patients with renal impairment, including severe impairment, and the elderly (aged ≥70 years). Linagliptin is the first DPP-4 inhibitor to be eliminated primarily via a nonrenal route, enabling its use without dosage adjustment in patients with any degree of renal impairment. Linagliptin is generally well tolerated and, as with other DPP-4 inhibitors, it is associated with a low risk of hypoglycaemia and has no effect on bodyweight. Some data indicate that linagliptin may have beneficial effects on cardiovascular and renal safety profiles in patients with type 2 diabetes, but more data are needed. Meanwhile, the low risk of hypoglycaemia and the nonrenal route of elimination may provide important advantages for some patient groups, including elderly or renally impaired patients.

01 Sep 2013·Revue medicale de Liege

[Jentadueto, fixed combination of linagliptin plus metformin for the treatment of type 2 diabetes].

Review

Author: Scheen, A J ; Van Gaal, L F

In case of failure of metformin monotherapy, several pharmacological strategies may be considered for the treatment of type 2 diabetes. Among these, the addition of an inhibitor of the dipeptidyl peptidase-4 (DPP-4) enzyme, a medication commonly named as gliptin, is increasingly used because of two main advantages over sulfonylureas, i.e. the absence of both hypoglycaemia and weight gain. The combination of a gliptin and metformin further improves glycaemic control compared to either monotherapy, due to complementary mechanisms of action. Most patients with type 2 diabetes are treated every day with numerous drugs because of the presence of comorbidities so that poor drug compliance is a major concern in such a population. The use of fixed-dose combinations (FDCs) may improve compliance and, therefore, several gliptin-metformin FDCs are now available. The most recent one is Jentadueto, which combines linagliptin, a selective DPP-4 inhibitor without renal excretion, and metformin, the first-line antidiabetic compound. This FDC is commercialized with two dosages of metformin, i.e. 2.5 mg linagliptin/850 mg metformin and 2.5 mg linagliptin/1.000 mg metformin, and should be administered twice daily with meal.While linagliptin may be prescribed whatever the renal function, the use of FDC should take into account classical restrictions imposed by the presence of metformin.

News (Medical) associated with Linagliptin/Metformin Hydrochloride

29 Aug 2025

·www.einpresswire.com

July - September 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

Ajovy (fremanezumab-vfrm) Emgality (galcanezumab-gnlm) Nurtec ODT (rimegepant) Ubrelvy (ubrogepant) Vyepti (eptinezumab-jjmr) Hypertension The "Warnings and Precautions", "Adverse Reactions", "Patient Counseling Information", and "Patient Information" sections of the labeling were updated in March 2025 to include information about the risk of hypertension. Example: Ajovy labeling Apriso (mesalamine) Asacol (mesalamine) Asacol HD (mesalamine) Azulfidine (sulfasalazine) Azulfidine EN-Tabs (sulfasalazine) Canasa (mesalamine) Colazal (balsalazide disodium) Delzicol (mesalamine) Dipentum (osalazine sodium) Giazo (balsalazide disodium) Lialda (mesalamine) Rowasa (mesalamine) Pentasa (mesalamine) Severe cutaneous adverse reactions The Warnings and Precautions section of the labeling was updated November 2021 to include severe cutaneous adverse reactions. Example: Delzicol labeling Avastin (bevacizumab) Mvasi (bevacizumab-awwb) Zirabev (bevacizumab-bvzr) Pancreatitis FDA determined that no action is necessary at the time based on available information. Avastin (bevacizumab) Mvasi (bevacizumab-awwb) Zirabev (bevacizumab-bvzr) Anaphylactic shock The "Warnings and Precautions" section of the labeling was updated between September 2022 and February 2023 to include anaphylactoid/anaphylactic reactions. Example: Avastin labeling Ayvakit (avapritinib) Photosensitivity reaction The "Warnings and Precautions", "Adverse Reactions", "Patient Counseling Information", and "Patient Information" sections of the labeling were updated in March 2023 to include information about photosensitivity. Ayvakit labeling Azacitidine Onureg (azacitidine) Vidaza (azacitidine) Generic products containing azacitidine Pericarditis The "Adverse Reactions" section of the labeling was updated between September 2022 and June 2023 to include pericarditis. Example: Vidaza labeling FDA determined that no action is necessary at the time based on available information for Onureg. Bavencio (avelumab) Imfinzi (durvalumab) Libtayo (cemiplimab-rwlc) Keytruda (pembrolizumab) Opdivo (nivolumab) Tecentriq (atezolizumab) Yervoy (ipilimumab) Tumour lysis syndrome FDA determined that no action is necessary at the time based on available information. Cymbalta (duloxetine hydrochloride) Drizalma Sprinkle (duloxetine hydrochloride) Generic products containing duloxetine hydrochloride Anosmia, Hyposmia This issue is posted as two individual newly identified safety signal (NISS) entries in the January-March 2022 quarter, to reflect the focus on the potential signals of anosmia and hyposmia, separately. Darzalex (daratumumab) Darzalex Faspro (daratumumab and hyaluronidase-fihj) Blood stem cell transplant failure FDA determined that no action is necessary at the time based on available information. Dipeptidyl peptidase-4 (DPP-4) inhibitors Glyxambi (empagliflozin and linagliptin) Janumet (metformin hydrochloride and sitagliptin phosphate) Janumet XR (metformin hydrochloride and sitagliptin phosphate) Jentadueto (linagliptin and metformin hydrochloride) Jentadueto XR (linagliptin and metformin hydrochloride) Kazano (alogliptin and metformin hydrochloride) Kombiglyze XR (metformin hydrochloride and saxagliptin) Nesina (alogliptin) Onglyza (saxagliptin) Oseni (alogliptin and pioglitazone) Steglujan (ertugliflozin and sitagliptin) Tradjenta (linagliptin) Trijardy XR (empagliflozin, linagliptin and metformin hydrochloride) Qtern (saxagliptin and dapagliflozin) Generic products containing dipeptidyl peptidase-4 inhibitors Tubulointerstitial nephritis The "Adverse Reactions" section of the labeling was updated between March 2022 and June 2022 for products containing alogliptin and sitagliptin to include tubulointerstitial nephritis. Example: Janumet labeling FDA determined that no action is necessary for products containing linagliptin and saxagliptin at the time based on available information. *An administrative error resulted in the omission of Januvia from the list of product names after the initial quarterly report was posted. Dupixent (dupilumab) Angioedema The "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in December 2021 to include angioedema. Dupixent labeling Glucagon-like peptide-1 (GLP-1) analogues Adlyxin (lixisenatide) Bydureon (exenatide) Bydureon BCise (exenatide) Byetta (exenatide) Ozempic (semaglutide) Rybelsus (semaglutide) Saxenda (liraglutide) Soliqua 100/33 (insulin glargine and lixisenatide injection) Trulicity (dulaglutide) Victoza (liraglutide) Wegovy (semaglutide) Xultophy 100/3.6 (insulin degludec and liraglutide injection) Generic products containing glucagon-like peptide-1 analogues Gallbladder related disorders The "Warnings and Precautions", "Adverse Reactions", and "Patient Counseling Information" sections of the GLP-1 analogues labeling were updated between March 2022 and June 2022 to include information about acute gallbladder disease. Example: Adlyxin labeling FDA has determined that the last approved labeling for Saxenda and Wegovy is adequately labeled for acute gallbladder disease, and that no further regulatory action is needed at this time. Gonadotropin releasing hormone (GnRH) analogues Fensolvi (leuprolide acetate) Lupron Depot-PED (leuprolide acetate) Supprelin LA (histrelin acetate) Synarel (nafarelin acetate) Triptodur (triptorelin) Idiopathic intracranial hypertension The "Warnings", "Precautions", and "Adverse Reactions" sections of the labeling were updated in April 2022 to include idiopathic intracranial hypertension. Example: Fensolvi labeling Jakafi (ruxolitinib phosphate) Herpes simplex virus (HSV) reactivation and/or disseminated HSV The "Dosage and Administration", "Warnings and Precautions", and "Adverse Reactions" sections of the labeling were updated in January 2023 to include information about herpes simplex and herpes zoster infections. Jakafi labeling Ibrance (palbociclib) Kisqali (ribociclib) Kisqali Femara Co-Pack (letrozole and ribociclib) Embolic and thrombotic events, venous The "Adverse Reactions" section of the Ibrance labeling was updated in December 2024 to include venous thromboembolism. Ibrance labeling FDA determined that no action is necessary at the time for Kisqali and Kisqali Femara Co-Pack based on available information. Ocrevus (ocrelizumab) Myocardial infarction FDA determined that no action is necessary at the time based on available information. Potassium Chloride Product preparation error The “Warnings” section of the labeling was updated in December 2022 to include information about fatal cardiac adverse reactions with intravenous administration of undiluted potassium chloride. Praxbind (idarucizumab) Wrong dose errors The carton labeling and "Dosage and Administration" sections of the labeling were revised in February 2022 to clarify the number of vials included in each carton and the recommended dosing. Praxbind labeling Qbrexza (glycopyrronium tosylate) Accidental exposure to product The container label, carton labeling, "Dosage and Administration", "Warnings and Precautions", "Patient Counseling Information", and "Patient Information" sections of the labeling were updated in October 2022 to include information about accidental exposure. Qbrexza labeling Qbrexza (glycopyrronium tosylate) Urinary retention The “Warnings and Precautions”, “Adverse Reactions”, and “Patient Counseling Information” sections of the labeling were updated in October 2022 to include information about new or worsening urinary retention. Qbrexza labeling Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Farxiga (dapagliflozin) Glyxambi (empagliflozin and linagliptin) Invokamet (canagliflozin and metformin hydrochloride) Invokamet XR (canagliflozin and metformin hydrochloride) Invokana (canagliflozin) Jardiance (empagliflozin) Qtern (saxagliptin and dapagliflozin) Steglatro (ertugliflozin) Steglujan (ertugliflozin and sitagliptin) Segluromet (ertugliflozin and metformin hydrochloride) Synjardy (empagliflozin and metformin hydrochloride) Synjardy XR (empagliflozin and metformin hydrochloride) Trijardy XR (empagliflozin, linagliptin and metformin hydrochloride) Xigduo XR (dapagliflozin and metformin) Generic products containing sodium-glucose cotransporter-2 (SGLT-2) inhibitors Tubulointerstitial nephritis FDA determined that no action is necessary at the time based on available information. Somatostatin Receptor Imaging Agents Detectnet (copper Cu-64 dotatate injection) Gallium Dotatoc (GA 68) Octreoscan (Indium In 111 Pentetreotide) Netspot (Gallium GA 68 Dotatate) Hypersensitivity The "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in December 2021 to include hypersensitivity reactions. Example: Netspot labeling Stromectol (ivermectin) Generic products containing ivermectin Off label use FDA determined that no action is necessary at the time based on available information. Stromectol (ivermectin) Generic products containing ivermectin Neurotoxicity The "Warnings", "Adverse Reactions", and "Overdosage" sections of the labeling were updated in March 2022 to include neurotoxicity. Example: Stromectol labeling Sunosi (solriamfetol hydrochloride) Hypersensitivity FDA determined that no action is necessary at the time based on available information. Vivitrol (naltrexone) Incorrect route of product administration The container label (vial), carton labeling, "Dosage and Administration", "Warnings and Precautions", and "Description", sections of the labeling were revised in September 2022 to emphasize the appropriate route and site of administration. Vivitrol labeling Xcopri (cenobamate) Psychiatric disorders The "Adverse Reactions" section of the labeling was updated in June 2022 to include psychiatric disorders. Xcopri labeling Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug Approval

28 Jan 2020

·www.biospace.com

Boehringer Ingelheim and Lilly’s Blood Sugar Combo Pill Approved

The approval was based on two randomized open-label clinical trials that evaluated the combination of empagliflozin, linagliptin and metformin and their individual components in healthy adults. The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company ’s Trijardy XR for lowering blood sugar in adults with type 2 diabetes. Trijardy XR is a triple-combination pill that includes Jardiance (empagliflozin), Tradjenta (linagliptin) and metformin hydrochloride extended release. It is prescribed along with diet and exercise for decreasing blood glucose levels in type 2 diabetes. In the U.S., Jardiance and Radjenta are once-daily tablet used to treat adults with type 2 diabetes. Jardiance has also been approved to decrease the risk of cardiovascular death in adults with type 2 diabetes with known cardiovascular disease. It is not approved for type 1 diabetes or for individuals with diabetic ketoacidosis. Tradjenta is also not prescribed for type 1 diabetic patients or for diabetic ketoacidosis. “Many adults living with type 2 diabetes who are already on a treatment plan including multiple medications still struggle to keep their blood sugar under control, and may require additional agents to reach their A1C targets,” said Ralph DeFronzo, professor and diabetes division chief, UT Health San Antonio. “Adding new medicines to an individual’s plan can be challenging for some, which is why new treatment options that can help improve blood sugar without the burden of an increased pill count are important.” DeFronzo added, “Type 2 diabetes is a complex disease that often requires the use of multiple antidiabetic medications to improve glycemic control. Having three different diabetes medications in a single tablet is an important advance in diabetes treatment.” The approval was based on two randomized open-label clinical trials that evaluated the combination of empagliflozin, linagliptin and metformin and their individual components in healthy adults. The safety pro Trijardy XR was consistent with the individual components. The drug combination will be available in four different dosages of the three different drugs, empaglifozin/linagliptin/metformin: 5mg/2.5mg/1000mg; 10mg/5mg/1000mg; 12.5mg/2.5mg/1000mg; and 25mg/5mg/1000mg. Jardiance is also in two other two-drug combinations , Glyxambi/Jentuadueto (empagliflozin/linagliptin) and Synjardy (empagliflozin/metformin). Boehringer is expected to report more than $2 billion in Jardiance-related product sales for 2019, while Lilly indicated it brought in about $677 million from the franchise in the first three quarters of 2019. Jardiance was initially launched in 2014 and is the top-selling SGLT2 inhibitor in the U.S., commanding about a 50% market share in the U.S. and a 41% market share worldwide. Its closest competitor is AstraZeneca’s Farxiga (dapagliflozin). AstraZeneca reported $1.1 billion Farxiga sales in the first quarter of 2019 alone. On January 17, Alembic Pharmaceuticals received tentative approval from the FDA for its generic of Jardiance. Mohamed Eid, vice president, Clinical Development & Medical Affairs, Cardio-Metabolism & Respiratory Medicine for Boehringer, said, “We are proud to offer Trijardy XR as a new once-daily option combining three well-established medicines, including an extended-release version of metformin, the most commonly prescribed initial treatment for type 2 diabetes, Jardiance, the most prescribed SGLT2 inhibitor, and Tradjenta, the only single-dose DPP-4 inhibitor. We believe Trijardy XR has the potential to help adults with type 2 diabetes conveniently manage their treatment, especially those who are taking other medications and working on the necessary lifestyle changes.”

Drug Approval

100 Deals associated with Linagliptin/Metformin Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	A10BD11	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	United States	Boehringer Ingelheim Pharmaceuticals, Inc.	30 Jan 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02121509 (CTgov)	Phase 1	-	74	linagliptin+metformin (L+M 1500 Fasted)	qengfwqynf(kdpnwrouqc) = zxavpakzer abrfixsizi (ekczewmdlo, 11.5) View more	-	04 Aug 2016
				linagliptin+metformin (FDC 1500 Fasted)	qengfwqynf(kdpnwrouqc) = hkblcnabrq abrfixsizi (ekczewmdlo, 11.5) View more
NCT02084056 (CTgov)	Phase 1	-	74	linagliptin+metformin (L+M 2000 Fasted)	cnontcjlod(slxbeucgne) = gkangglprb bwntdweuwn (tjdrmomust, 9.1) View more	-	04 Aug 2016
				linagliptin+metformin (FDC 2000 Fasted)	cnontcjlod(slxbeucgne) = hmnxhbptrl bwntdweuwn (tjdrmomust, 9.1) View more
NCT02084082 (CTgov)	Phase 1	-	68	linagliptin+metformin (L+M 1000 Fasted)	zvlkykkqqv(jpedyjvkwv) = zvqhkflbxs qpcypflwea (kyuskeqlwd, 11.8) View more	-	04 Aug 2016
				linagliptin+metformin XR (FDC 1000 Fasted)	zvlkykkqqv(jpedyjvkwv) = cnjdcunmxc qpcypflwea (kyuskeqlwd, 11.8) View more
NCT01708902 (EASD2015)	Phase 3	Diabetes Mellitus, Type 2	733	Linagliptin 5 mg QD	wrochfujbj(tjysljuqgl) = low across groups sudsmyjsri (qgntqgdohh ) View more	Positive	17 Sep 2015
				Metformin 500 mg BID
NCT01845077 (CTgov)	Phase 1	-	72	linagliptin+metformin (FDC1000 Fasted)	bkglzzplox(otkvgaoyjx) = mqmeeiaofy alledbtnir (ibbbsowaya, 8.0) View more	-	19 Aug 2014
				linagliptin+metformin (L+M1000 Fasted)	bkglzzplox(otkvgaoyjx) = rbwcfdvwei alledbtnir (ibbbsowaya, 8.0) View more
NCT01581931 (CTgov)	Phase 1	-	32	Met (Lina+Met Single Tablets)	nnxsxlhczg(znkeclngqy) = vvefzttqck lnsmwjrsjo (qkgpobkcnl, 9.8) View more	-	20 Aug 2013
				Met (Lina+Met FDC Tablet)	nnxsxlhczg(znkeclngqy) = hjdolgdoyl lnsmwjrsjo (qkgpobkcnl, 9.8) View more
NCT01540487 (CTgov)	Phase 1	-	48	Linagliptin+Metformin (Linagliptin 2.5 mg, Metformin 850 mg as FDC Tablet)	vojlnhdseb(igrilrvauy) = tohfbtljpn arbhrsvvgh (tdwradmpbl, 14.5) View more	-	06 Aug 2013
				Linagliptin+Metformin (Linagliptin 2.5 mg, Metformin 850 mg as Single Tablets)	vojlnhdseb(igrilrvauy) = ueiqyiewai arbhrsvvgh (tdwradmpbl, 15.3) View more
NCT01383356 (CTgov)	Phase 1	Diabetes Mellitus, Type 2	58	Met (Lina/Met 2.5mg/500mg)	lsikztvnht(fmpqyrtywz) = fxfrhuzqgk muktofbaci (hrhvcauqou, 262.45) View more	-	24 Jan 2013
				Met (Lina 2.5mg Plus Met 500mg)	lsikztvnht(fmpqyrtywz) = fzcudluhsj muktofbaci (hrhvcauqou, 189.44) View more
NCT01216397 (CTgov)	Phase 1	-	40	linagliptin+metformin (Standard Batch)	sovhltbetp(abupaiaygc) = uytlydfpji mselyokrzh (oudlrqginb, 20.3) View more	-	25 Apr 2012
				linagliptin+metformin (Side Batch)	sovhltbetp(abupaiaygc) = nnxldojwak mselyokrzh (oudlrqginb, 20.3) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Linagliptin/Metformin Hydrochloride

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation